- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exenatide SC, Exenatide IV, Placebo SC, Exendin-9, Placebo IV
- Drug
- Lead sponsor
- Carl T. Hayden VA Medical Center
- Federal
- Eligibility
- 35 Years to 70 Years
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 30
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms
- Interventions
- Exendin 9-39, Microlipid, Placebo
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 104 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Hyperinsulinemia Hypoglycemia
- Interventions
- Exendin (9-39)
- Drug
- Lead sponsor
- Tracey McLaughlin
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Gestational Diabetes Mellitus
- Interventions
- Exendin 9-39
- Drug
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 20 Years to 40 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Obesity, PreDiabetes
- Interventions
- Liraglutide, Sitagliptin, hypocaloric diet, Placebos, Exendin (9-39)
- Drug · Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 329 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin9
- Drug
- Lead sponsor
- Blandine Laferrere
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- PreDiabetes
- Interventions
- Exendin 9-39, Saline
- Biological
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Postbariatric Hypoglycemia
- Interventions
- exendin 9-39, Placebo
- Drug · Other
- Lead sponsor
- Eiger BioPharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 5
- States / cities
- Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more
- Conditions
- Acquired Hyperinsulinemic Hypoglycemia
- Interventions
- Avexitide
- Drug
- Lead sponsor
- Dr. Tracey McLaughlin, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Monogenic Diabetes
- Interventions
- GLP-1, Exendin 9-39
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Insulin Secretion
- Interventions
- Glucagon
- Drug
- Lead sponsor
- David D'Alessio, M.D.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Post Bariatricsurgery, Hypoglycemia
- Interventions
- Exendin-(9-39), Atropine, GLP-1 and GIP
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Exendin 9, 39, Placebo
- Drug
- Lead sponsor
- Adrian Vella
- Other
- Eligibility
- 20 Years to 70 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Post-bariatric Hypoglycemia
- Interventions
- Avexitide
- Drug
- Lead sponsor
- Amylyx Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years and older
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Morehead City, North Carolina • Mesquite, Texas + 1 more
- Conditions
- Genetic Predisposition, Type2diabetes
- Interventions
- Exendin 9-39, Saline
- Biological · Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 25 Years to 70 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Insulin Secretion
- Interventions
- Exendin (9-39), Dexamethasone, Hyperglycemic Clamp
- Drug · Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin-(9-39), Vehicle
- Drug · Other
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 7 Years to 60 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes
- Interventions
- Exendin (9-39), acyl ghrelin, saline
- Drug
- Lead sponsor
- David Dalessio
- Other
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Cincinnati, Ohio
- Conditions
- Postprandial Hypoglycemia
- Interventions
- Exendin-(9-39), Vehicle
- Drug · Other
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Post-bariatric Surgery
- Interventions
- exendin -(9-39)
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas
- Conditions
- Obesity
- Interventions
- Sitagliptin, Pegvisomant, Placebo, L-NMMA, Exendin 9-39
- Drug
- Lead sponsor
- Vanderbilt University
- Other
- Eligibility
- 18 Years to 40 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2017
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Congenital Hyperinsulinism
- Interventions
- Exendin-(9-39), placebo
- Drug
- Lead sponsor
- Diva De Leon
- Other
- Eligibility
- 6 Months to 18 Years
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Heart Disease
- Interventions
- Exendin-9, GLP-1, saline
- Drug · Other
- Lead sponsor
- David Dalessio
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Post Bariatric Surgery, Gastric Bypass, Sleeve Gastrectomy, Hypoglycemia After Gastric Bypass
- Interventions
- Exendin-(9-39), Atropine
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2027
- U.S. locations
- 2
- States / cities
- San Antonio, Texas